Patents matching “ONC”

US 8372872

Methods for concomitant treatment of theophylline and febuxostat

Takeda Pharmaceuticals U.S.A., Inc. · Granted Feb 12, 2013 · Expires Feb 7, 2033

WO 2013015774

DIHYDROXY-CHLORINES GLYCO-SUBSTITUÉES ET CHLORINES BÊTA-FONCTIONNALISÉES POUR THÉRAPIE ANTIMICROBIENNE PHOTODYNAMIQUE

BIOLITEC PHARMA MARKETING LTD [MY] · Granted Jan 31, 2013 · Expires Jan 26, 2033

US 8357379

High concentration baclofen preparations

The Board of Regents of the University of Texas System · Granted Jan 22, 2013 · Expires Jan 17, 2033

US 8323634

Stable formulations of highly concentrated recombinant human albumin-human granulocyte colony stimulating factor

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Dec 4, 2012 · Expires Nov 29, 2032

US 8206740

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Jun 26, 2012 · Expires Jun 21, 2032

US 8147845

Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions

ONCOLYTICS BIOTECH INC. · Granted Apr 3, 2012 · Expires Mar 29, 2032

US 8080241

Viruses for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Dec 20, 2011 · Expires Dec 15, 2031

US 8071087

Reovirus for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Dec 6, 2011 · Expires Dec 1, 2031

US 8066985

Reovirus for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Nov 29, 2011 · Expires Nov 24, 2031

US 8062647

High concentration baclofen preparations

The Board of Regents of the University of Texas System · Granted Nov 22, 2011 · Expires Nov 17, 2031

US 8008038

Methods for determining oxygen concentration with protoporphyrin IX

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM · Granted Aug 30, 2011 · Expires Aug 25, 2031

US 7964187

Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus

ONCOLYTICS BIOTECH INC. · Granted Jun 21, 2011 · Expires Jun 16, 2031

US 7964186

Viruses for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Jun 21, 2011 · Expires Jun 16, 2031

US 7906535

High concentration topical insecticides containing pyrethroids

Summit VetPharm, LLC · Granted Mar 15, 2011 · Expires Mar 10, 2031

US 7901921

Viral purification methods

ONCOLYTICS BIOTECH INC. · Granted Mar 8, 2011 · Expires Mar 3, 2031

US 7824697

High concentration baclofen preparations

The Board of Regents of the University of Texas System · Granted Nov 2, 2010 · Expires Oct 28, 2030

US 7815914

Methods for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Oct 19, 2010 · Expires Oct 14, 2030

US 7803385

Reoviruses having modified sequences

ONCOLYTICS BIOTECH INC. · Granted Sep 28, 2010 · Expires Sep 23, 2030

US 7799329

Viruses for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Sep 21, 2010 · Expires Sep 16, 2030

US 7781448

Once daily dosage forms of trospium

Supernus Pharmaceuticals, Inc. · Granted Aug 24, 2010 · Expires Aug 19, 2030

US 7771729

Methods of potentiating HIV-1-specific CD8+ immune responses involving the concomitant administration of DNA and ALVAC expression vectors

The United States of America, as represented by the Department of Health and Human Services · Granted Aug 10, 2010 · Expires Aug 5, 2030

US 7763635

Once daily dosage forms of trospium

Supernus Pharmaceuticals, Inc. · Granted Jul 27, 2010 · Expires Jul 22, 2030

US 7763252

Methods for the treatment of cellular proliferative disorders

ONCOLYTICS BIOTECH INC. · Granted Jul 27, 2010 · Expires Jul 22, 2030

US 7759359

Method of treating bladder dysfunction with once-a-day trospium salt formulation

Supernus Pharmaceuticals, Inc. · Granted Jul 20, 2010 · Expires Jul 15, 2030